1
|
Wu Z, Wang C, Liu B, Liang C, Lu J, Li J, Tang X, Li C, Li T. Smartphone-Based High-Throughput Fiber-Integrated Immunosensing System for Point-of-Care Testing of the SARS-CoV-2 Nucleocapsid Protein. ACS Sens 2022; 7:1985-1995. [PMID: 35766020 PMCID: PMC9261833 DOI: 10.1021/acssensors.2c00754] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2022] [Accepted: 06/15/2022] [Indexed: 11/28/2022]
Abstract
To control the coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need for simple, rapid, and reliable detection methods to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, especially in community hospitals or clinical centers. The SARS-CoV-2 nucleocapsid protein (NP) is an important index for diagnosis of COVID-19. Here, we proposed a smartphone-based high-throughput fiber-integrated immunosensing system (HFIS) for detecting the SARS-CoV-2 NP in serum samples within 45 min. For the testing of NP standards, the linear detection range was 7.8-1000 pg/mL, the limit of detection was 7.5 pg/mL, and the cut-off value was 8.923 pg/mL. Twenty-five serum samples from clinically diagnosed COVID-19 patients and 100 negative control samples from healthy blood donors were tested for SARS-CoV-2 NP by HFIS, and the obtained results were compared with those of ELISA and Simple Western analysis. The results showed that the HFIS sensitivity and specificity were 72% [95% confidence interval (CI): 52.42-85.72%] and 100% (95% CI: 96.11-100%), respectively, which significantly correlated with those from the commercial ELISA kit and Simple Western analysis. This portable high-throughput HFIS assay could be an alternative test for detecting SARS-CoV-2 NP in blood samples on site.
Collapse
Affiliation(s)
- Ze Wu
- Department of Transfusion Medicine, School of
Laboratory Medicine and Biotechnology, Southern Medical
University, Guangzhou 510515, P. R. China
- Department of Laboratory Medicine, Nanfang Hospital,
Southern Medical University, Guangzhou 510515, P. R.
China
| | - Cong Wang
- Department of Transfusion Medicine, School of
Laboratory Medicine and Biotechnology, Southern Medical
University, Guangzhou 510515, P. R. China
| | - Bochao Liu
- Department of Transfusion Medicine, School of
Laboratory Medicine and Biotechnology, Southern Medical
University, Guangzhou 510515, P. R. China
- Guangzhou Blood Center,
Guangzhou 510091, P. R. China
| | - Chaolan Liang
- Department of Transfusion Medicine, School of
Laboratory Medicine and Biotechnology, Southern Medical
University, Guangzhou 510515, P. R. China
| | - Jinhui Lu
- Department of Transfusion Medicine, School of
Laboratory Medicine and Biotechnology, Southern Medical
University, Guangzhou 510515, P. R. China
| | - Jinfeng Li
- Shenzhen Key Laboratory of Molecular Epidemiology,
Shenzhen Center for Disease Control and Prevention, Shenzhen
518054, P. R. China
| | - Xi Tang
- Department of Infection, The First
People’s Hospital of Foshan, Foshan 528010,
China
| | - Chengyao Li
- Department of Transfusion Medicine, School of
Laboratory Medicine and Biotechnology, Southern Medical
University, Guangzhou 510515, P. R. China
| | - Tingting Li
- Department of Transfusion Medicine, School of
Laboratory Medicine and Biotechnology, Southern Medical
University, Guangzhou 510515, P. R. China
| |
Collapse
|